Analyst Says Acelyrin (SLRN) Dosing Errors Create “Too Much Uncertainty,” Securities Class Action Pending - Hagens Berman
29 déc. 2023 13h50 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...